OncBioMune signs MOU for JV with Vitel to develop novel cancer vaccine for Mexico and Latin America
The initial focus of the JV will be immediately advancing ProscaVax, OncBioMune’s novel prostate cancer vaccine combining a tumor-associated antigen with biological adjuvants, into a Phase 2A/2B clinical
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.